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The clinical effectiveness of topical hydrocortisone preparations in the treatment of
eczematous and other acute inflammatory dermatoses has been recorded by numerous ob-
servers (1—4). While tbe beneficial anti-inflammatory effects produced by hydrocortisone
suggest some absorption of the hormone into the skin, no direct evidence for this assump-
tion has previously been presented. Salt retention, edema and weight gain, hypertension,
and other side-effects that might denote systemic absorption have not been reported.
Smith (5) noted no change in circulating eosinophile counts following a single iaunction of
150 mgm. of hydrocortisone acetate in ointment base into the skin of each of 8 normal
adults and 7 patients with generalized skin disease. Working with 6 normal subjects and 9
patients with generalized dermatoses, Witten and his associates (6) applied 750 mgm. of
hydrocortisone incorporated into an ointment base to large areas of the skin snrface over a
3-day period; colorimetric tests for 17,21-dihydroxy-20 ketosteroids demonstrated no sig-
nificant differences between pre-inunctioa and post-inunction levels in the blood or urine.
Fitzpatrick ct eli. (7) studied urinary hydrocortisone excretion in two patients with gen-
eralized atopic dermatitis after daily application for 7 days of 2.5 Cm. of hydrocortisone
in a lotion base and found no increase of compound F in the urine.
When HellInan and co-workers (8) showed that 70—80% of hydrocortisoae-4-C' given
intravenously to human subjects appeared in the urine within the first 24 hours, it was
decided to test percutaneous absorption of hydrocortisone by applying the same labeled
steroid in ointment form to normal human skin and by examining the 17-ketosteroid frac-
tion of the urine for radioactivity.
METhOD
The studies were performed on 2 hospitalized subjects, one of whom (patient 1) was a
41-year-old female with severe bullous dysidrosis of the hands and the other (patient 2)
a 58-year-old female with abdominal herpes zoster. Both patients were otherwise in good
health and liver function studies were within normal limits.
5 microcuries of hydrocortisone-4-C'4t (free alcohol) weighing 1.25 mgm. and having a
specific activity of 1.47 mc/m mole were incorporated with 11.25 mgm. of non-radioactive
"carrier" hydrecortisone into 0.5 Cm. of a cholesterolized petrolatum hase4 Application
of this 2.5% hydrocortisone ointment was made to a 39 square centimeter area of normal
skin ever the flexor aspect of the forearm and the material was rubbed in sufficiently to
provide a thin film over the skin surface. The amounts applied were 59 mgm. of ointment
containing 0.15 mgm. of C'4 labeled hydrocortisone to patient * 1 and 111 mgm. of ointment
containing 0.28 mgm. of C'4 labeled hydrecertisone to patient 2. The sites of application
remained covered for 6 days with a perforated aluminum eye patch taped firmly to the skin,
and daily 24-hour urine specimens were collected throughout this period. In patient 2 an
initial 9-hour urine sample was obtained before the regular 24-hour collections were begun.
After 6 days the dressings were removed and urine collections were discontinued.
* From the Section of Dermatology, Department of Medicine, University of Chicago.
(Chief of Service: Stephen Rothman, M.D.)
Received for publication September 12, 1955.
t This material was kindly supplied to us by the National Institutes of Health through
Dr. Sam R. Hall.
This base contains petrolatum, cholesterol, multiwax, and mineral oil. It is the stand-
ard vehicle for the hydrocortisone ointment preparations of the Upjohn Company, Kala-
mazoo, Michigan.
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TABLE 1
Patient no. 1
Urine (24 hnur specimens)
Planchet net counts per minute (actual count
minusbackground)
Calculated total disintegrations per minute (24
hr. specimen)
#1 #2 #3 #4 #5 #6
9.8
286
6.5
62
22.8
6512
*
*
15.4
286
11.3
382
* Lost.
TABLE 2
Patient no. 2
Urine (24 ilnuc Specimens)
Planchet net counts per minute (actual
countminusbackground)
Calculated total disintegrations per mm.
(24 hour specimen)
#1
0.0*
#2
31.0
1089
#3
33.9
764
#4 #5
21.6f 5.6
1012t1 303
$ 6
t
#7
5.2
208
* 9 hour specimen.
t Excessive non-radioactive residue in extract.
t Specimen used for paper chromatography—see text.
The 17-ketosteroid fraction of the urine was isolated by the method of Koch, modified
by Landau (9) as follows:
1) 38% hydrochloric acid was added to each 24-hour urine specimen in an amount equal
to 10% of the volume of the specimen. The resultant mixture was boiled for 15 minutes
under a reflux condenser and allowed to cool.
2) 500 cc. aliquots of the acidified urine were extracted 3 times for 3 minutes each with
75 cc. of anhydrous absolute ether. The extraction series were then combined and washed
with distilled water.
3) The ether was distilled off and the residue redissolved in absolute alcohol. After the
alcohol was blown off with nitrogen the remaining extract was weighed, and an aliquot of
known weight was transferred to a planchet for measurement of radioactivity in a gas
flow counter. It was not possible, however, to place an identical amount of material in the
planchet for each urine extract examined.
Disintegrations per minute were calculated for each total extract on a weight basis fol-
lowing determinations of net counts per minute for the planchet sample. Not all of the
urine extracts were satisfactorily homogeneous and in those that were not radioactivity
was unevenly distributed. Therefore, additional refinements of the method used would he
required to arrive at more precise quantitative results.
aEsULTs
No radioactivity was detectable in the first 9 hours after application of hydrocortisone-
4-C'4 to patient fl, but within 24 hours significant activity had appeared in the urine of
patient *' 1. (See tables 1 and 2.) The peak of excretion of radioactive material was reached
in the second 24-hour period, following which activity fell to relatively low levels by the
4th day and persisted essentially unchanged until observations ceased after the 6th day.
Examination of the 5th 24-hour urine specimen from patient 4 2* revealed that after paper
* This analysis was carried out by Dr. Harold Werbin, Argonne Cancer Research Hos-
pital.
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chromatography and elution the mixture of tetrahydrocortisone (THE) and tetrahydro-
hydrocortisone (THF) had a specific activity of 0.0199 mc/m. mole. This analysis clearly
indicated that radioactivity was present in a combination of at least 2 urinary compounds,
one of which (THF) is probably the chief hydrocortisone excretion product.
While precise quantitative data could not be determined, it was apparent that under the
conditions of the experiment less than 1% of the topically applied hydrocortisone-4-C14
was excreted in the urine over a period of 6 days. The excretion pattern observed suggests
that after an initial relatively high excretion rate a depot of hydrocortisone exists some-
where, perhaps in the skin, and that sma]l amounts of the hormone are steadily released
each day for many days.
SUMMARY
Percutaneous absorption of hydrocortisone through normal skin has been established
by detection of radioactivity in the urine following topical application of hydrocortisone-
4-C14 incorporated into an ointment base. Peak excretion of hydrocortisone occurred in the
second 24 hours after application, but lower levels of radioactivity persisted throughout
the 6-day experimental period. It is postulated from this excretion pattern that, following
initial percutaneous absorption and a relatively high excretion rate, a depot of hydrocor-
tisone forms, possibly in the skin, which persistently releases small amounts of the hor-
mone over an extended period of time.
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